Today, Dizal announced that it has entered into a global exclusive license agreement with AstraZeneca for Zegfrovy (sunvozertinib), a novel oral irreversible epidermal growth factor receptor (EGFR) inhibitor for patients with lung cancer. AstraZeneca will acquire worldwide rights to develop and commercialise Zegfrovy.Read More
Dizal Announces Global Exclusive License Agreement with AstraZeneca for Zegfrovy
By PR Newswire
